Puma Biotechnology raises 2026 guidance on NERLYNX demand, details alisertib trial timeline
Puma reported second quarter 2026 results and outlined milestones for its ALISCA alisertib program over the next 12 months while raising full-year revenue and net income guidance.
SEC filing